The Force Multiplier for the Biopharmaceutical Industry
It’s been a bumpy week in the markets. Before today’s AMA, let’s look at what’s going on…
The four-year biotech winter made no sense at all and was detrimental to advancing important therapies for a wide range of diseases. Happily, those days are over…
The big news that created a stir in high tech and finance in the last 48 hours was rumors and speculation that Elon Musk is gearing up to merge all – or at least two – of his companies together.
The two scenarios that are being discussed:
Years ago, Musk talked about creating one holding company, with the likely name of X, but nothing had been said about that recently.
The discussion since the beginning of the year had been focused on preparations for taking SpaceX public this year, perhaps as early as June. But something clearly shifted this week as a larger possible merger has received a lot of airtime.
As more details emerge, I’ll probably dig a little deeper on this topic next week.
Musk’s projects and companies are literally some of the most impactful contributions to humanity and economic growth in history. They are certainly worth our attention.
Have a great weekend,
Jeff
Jeff and Team,
Jeff, I have been following you for quite some time now. Started out before the pandemic and got burned like most in the biotechs. So much promise and hope, just withered on the vine. Cleaned up and rebalanced, was so excited when you came back.
I am a big fan of Musk’s companies and see them as a complete stack, not individual companies working in silos. You may have been a part of that.
I played with all the frontier AIs and have found Grok to be the best to suit my personality. I know that sounds weird, but if you have challenged all of them, you can feel the difference.
I frequently copy The Bleeding Edge and all of your research into Grok to help me learn more and dive deeper. It has been helpful professionally as an ER doc, personally for issues in the home, and with things like crypto and taxes, as well as how to deal with reframing and dealing with issues with in-laws. Very positive.
I use tonight’s Bleeding Edge and went a bit deeper on biotech. Just wonder what you think about the five companies in the Grok discussion that I have attached.
I would also like to hear what you think about the Musk stack of Tesla, Optimus, Starlink, Neuralink, X, xAI, and how they will all go together. My bet is in the next year, this group of companies will explode into or onto something nobody ever expected or even saw coming. In deep conversations, Grok agrees with me!!!
(Brownstone Unlimited, and so happy to be here).
– Dan K.
Hi Dan,
It’s great to have you with us as an Unlimited member. And thanks for the feedback, it has been great to be back and re-energized on my mission and vision for Brownstone Research.
Since the time that you wrote in, I’m very happy to say that I have re-launched coverage of the biotech sector with Early Stage Trader. Like you, it was painful to see the biotech market shrivel up due to the pandemic policies. The four-year biotech winter made no sense at all and was detrimental to advancing important therapies for a wide range of diseases.
Happily, those days are over, and I’ll be increasing biotech-related investment research in The Near Future Report (large-cap biotech), Exponential Tech Investor (think picks and shovels, IP, devices, and AI), and Early Stage Trader which is exclusively focused on early stage biotech companies in the pre-clinical or clinical stages with forthcoming catalysts that create high probability trading opportunities.
As an Unlimited member, you now have access to all my most recent research related to Early Stage Trader, including my first three alerts, and also three compelling biotech companies that I believe are most likely to be acquired by larger biopharma companies in 2026.
For anyone interested in learning more about the new and improved Early Stage Trader – our biotech-focused trading advisory – you can go here to catch the replay of our relaunch event from earlier this week.
As for the list you reference in your Grok conversation, I’m unable to provide any personalized investment advice on these companies, and I can’t perform my typical in-depth research on all these companies in The Bleeding Edge. So, I’ll just provide some general comments…
One of the companies I can’t mention, as it is already in our model portfolio in The Near Future Report. You – and any other Near Future Report subscribers – can find my full research on that company on our website right here.
As for Eli Lilly, I like the company, but don’t like the valuation right now. I simply believe that there are better companies to allocate to. Intellia and Denali are also two companies that I like, but I would need to perform a full analysis – and also do some work on valuation – before I could offer a strong position on either company.
As for Musk and his “stack” of technologies embedded within his various companies, there have been some developments in the last 48 hours that make this a very timely issue.
Musk has long alluded to a conglomerate model – most likely named X – to hold all of his businesses. But in the last two years or so, it hasn’t been mentioned at all, and the clear intentions to take SpaceX public in 2026 seemed to suggest those plans had changed. Musk, it appeared, would have two publicly traded companies and keep his artificial intelligence business, xAI, private.
This actually made a lot of sense. After all, xAI is developing artificial general intelligence (AGI), which confers an incredible competitive advantage. Not having to disclose the inner workings of xAI in SEC filings would be advantageous. Keeping xAI private for now is the smart move.
Prior to these merger talks, the silos that made sense to me were:
Another framework that is useful and fun for us to use is that all of his technologies are relevant in the context of making the human race a multiplanetary species:
Either way, Musk’s companies are destined to be the most important companies of our time. And combined, they will be the most valuable group of companies in history, which I believe will become worth tens of trillions of dollars.
No matter what happens, you can be sure that I’ll be on top of it with updates in The Bleeding Edge and in our model portfolios.
Love how you’re using Grok, really cool, proactive, and a great way to engage this incredible technology. And you are right, Grok is the best of them.
Hi Jeff, as a longtime subscriber, I enjoy your engineering insight. However, since Google launched the idea of data centers in space, I would have expected that you would address the idea and research the most capable companies to engineer such a space system and provide essential components: radiation-hardened chips/servers, optical communications, ground stations, physical/ cybersecurity, besides satellites and rockets. As I imagine only big and certified companies will do this, I think it fits perfectly in the Near Future theme.
Regards.
– Wolfgang B.
Hi Wolfgang,
This has definitely been a keen area of interest of mine as an emerging growth market to help solve some of the challenges and expenses of powering and cooling data centers here on Earth.
I covered Google’s Project Suncatcher last November in The Bleeding Edge – Space-Based Intelligence. In mid-December, in The Bleeding Edge – Necessity is the Mother of Invention, we had a look at Relativity Space and Starcloud, two companies working towards orbital data centers. And later that month, in The Bleeding Edge – NVIDIA Acquires” Groq, we dug a little deeper with looks at Star Catcher and Sophia Space. I recommend these issues to gain some additional perspective.
We also already have several companies in The Near Future Report and Exponential Tech Investor portfolios that will almost certainly feed into the orbital data center industry once it takes off. These companies range from semiconductor manufacturing to semiconductors, cybersecurity, and lasers/optics.
One thing to keep in mind, however, is that volumes of things like optical components or radiation-hardened semiconductors will be relatively low, especially in the next couple of years.
We can use Starlink as an example. Despite years of launching Starlink satellites, there are “only” about 9,400 in orbit today. While it’s the largest satellite constellation in history, the actual amount of semiconductor and optical content is rather small because there are only 9,400 satellites – not 9 million or 90 million satellites.
Gross margins for radiation-hardened components are typically much higher in the 70–80% range, but the volumes are much lower. This is why I didn’t include orbital data centers in my investment thesis for the companies in our model portfolios.
The key gating factor for the growth in orbital data centers is one company – SpaceX. Once SpaceX gets its Starship into commercial operations and launch costs per kilogram down to around $200, the economics make a lot of sense to launch data server satellites into orbit.
2026 will mark the beginning of this trend, and I am confident Starship launch costs will drop to attractive levels no later than 2027, so we’ll see a lot more investment next year in orbital compute.
This is definitely an industry we’ll track closely.
Jeff
Read the latest insights from the world of high technology.
It’s been a bumpy week in the markets. Before today’s AMA, let’s look at what’s going on…
At the beginning of this month, a long list of investors stepped up to invest $16 billion in Waymo...
This may very well be the most advanced AI-powered drug development breakthrough in history…
Thanks for signing up for The Bleeding Edge — we’re glad you’re here!
Want updates sent straight to your phone too? Sign up for SMS alerts to get the latest delivered via text.
Brownstone Research: By submitting your phone number, you agree to our SMS Terms & Conditions, Terms of Use, & Privacy Policy, and give express written consent to receive marketing text messages from BSR. Messages are recurring & frequency may vary. Reply STOP to 94703 to opt out. Reply HELP to 94703 for info. Consent is not a condition of purchase. Message and data rates may apply. For additional information, you may contact Customer Service at 888-512-0726 or smssupport@brownstoneresearch.com.